^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Rectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Krazati (adagrasib) (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/21/2023
    Excerpt:
    Rectal Cancer: SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE…Adagrasib + cetuximab (KRAS G12C mutation positive)…
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Colorectal Cancer)
    New
    Title:

    Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

    Excerpt:
    Bristol Myers Squibb...announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI ® (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C -mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.